0000899243-21-002119.txt : 20210114
0000899243-21-002119.hdr.sgml : 20210114
20210114205725
ACCESSION NUMBER: 0000899243-21-002119
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210112
FILED AS OF DATE: 20210114
DATE AS OF CHANGE: 20210114
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Hatzis-Schoch Brent
CENTRAL INDEX KEY: 0001637054
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39200
FILM NUMBER: 21530330
MAIL ADDRESS:
STREET 1: C/O RADIUS HEALTH, INC.
STREET 2: 950 WINTER STREET
CITY: WALTHAM
STATE: MA
ZIP: 02451
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Black Diamond Therapeutics, Inc.
CENTRAL INDEX KEY: 0001701541
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: ONE MAIN STREET, 10TH FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 617-417-5868
MAIL ADDRESS:
STREET 1: ONE MAIN STREET, 10TH FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
FORMER COMPANY:
FORMER CONFORMED NAME: Aset Therapeutics, Inc.
DATE OF NAME CHANGE: 20170321
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-01-12
0
0001701541
Black Diamond Therapeutics, Inc.
BDTX
0001637054
Hatzis-Schoch Brent
C/O BLACK DIAMOND THERAPEUTICS, INC.
ONE MAIN STREET, 10TH FLOOR
CAMBRIDGE
MA
02142
0
1
0
0
See Remarks
Common Stock
2021-01-12
4
M
0
4078
3.20
A
12478
D
Common Stock
2021-01-12
4
M
0
7500
10.86
A
19978
D
Common Stock
2021-01-12
4
S
0
2048
29.9236
D
17930
D
Common Stock
2021-01-12
4
S
0
1669
30.5043
D
16261
D
Common Stock
2021-01-12
4
S
0
147
31.9077
D
16114
D
Common Stock
2021-01-12
4
S
0
103
32.4974
D
16011
D
Common Stock
2021-01-12
4
S
0
100
34.125
D
15911
D
Common Stock
2021-01-12
4
S
0
7511
35.9999
D
8400
D
Stock Option (Right to Buy)
3.20
2021-01-12
4
M
0
4078
0.00
D
2029-06-11
Common Stock
4078
176786
D
Stock Option (Right to Buy)
10.86
2021-01-12
4
M
0
7500
0.00
D
2029-12-04
Common Stock
7500
71251
D
Shares sold pursuant to a pre-established 10b5-1 trading plan effective as of June 12, 2020
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.315 to $30.30, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.335 to $30.66, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.46 to $32.08, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.495 to $32.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.95 to $36.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
25% of the shares subject to this option vested and became exercisable on May 22, 2020, with the remainder vesting in 36 equal monthly installments thereafter.
25% of the shares subject to this option vested and became exercisable on December 5, 2020, with the remainder vesting in 36 equal monthly installments thereafter.
Chief Operating Officer and General Counsel
/s/ Brent Hatzis-Schoch
2021-01-14